INOVIQ Shares Surge On Positive In-Vitro Exosome Therapy Results For Breast Cancer

INOVIQ Ltd (ASX: IIQ) shares surged ~40% higher intra-day after successfully producing and isolating engineered exosomes (EEVs) that target and kill breast cancer cells in vitro.

In a proof-of-concept study, a breast cancer-targeting protein (a chimeric antigen receptor, CAR) was expressed in exosomes released by immune cells.

The modified exosomes were isolated and concentrated from immune cell-conditioned media using INOVIQ’s proprietary EXO-ACE technology.

Positive outcome

EXO-ACE recovered more than 80% of exosomes from cell-conditioned media with over 95% purity.

When treated with these exosomes, 75% of breast cancer cells underwent cell death within 72 hours.

Based on these significant results, INOVIQ will now progress its exosome therapeutics program, initially focusing on immune-cell derived exosome therapeutics for metastatic breast and ovarian cancers.

“Effective cancer therapy”

INOVIQ CEO Leearne Hinch said: “INOVIQ has established core capabilities in-house to engineer, load and produce exosomes for therapeutic applications.

“These data highlight the potential of immune-cell derived exosomes as an effective cancer therapy and the potential for RNA drug-loaded exosome therapeutics.”

 Promega distribution deal

In April, INOVIQ partnered with Promega Corporation to unlock the commercial potential of exosomes for research, diagnostic and therapeutic applications.

Read: INOVIQ Shares Rise After Signing Global Distribution Deal With Promega

This agreement will leverage INOVIQ’s EXO-NET pan-exosome capture tool and Promega’s expertise in nucleic acid purification systems.

Building upon last year’s successful co-marketing agreement, the three-year deal extends the commercial relationship between INOVIQ and Promega.

 

Disclaimer

JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest